Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis

Yasuhito Nerome; Hiroyuki Imanaka; Yukiko Nonaka; Syuji Takei

doi:10.1007/s10165-007-0634-3

Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis

Mod Rheumatol. 2007;17(6):526-8. doi: 10.1007/s10165-007-0634-3. Epub 2007 Dec 20.

Authors

Yasuhito Nerome¹, Hiroyuki Imanaka, Yukiko Nonaka, Syuji Takei

Affiliation

¹ Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan. [email protected]

PMID: 18084710
DOI: 10.1007/s10165-007-0634-3

Abstract

Tumor necrosis factor alpha (TNFalpha)-blocking agents have been used increasingly in the treatment of severe refractory juvenile idiopathic arthritis (JIA). However, some patients have been forced to discontinue these agents because of the lack of efficacy or adverse events. In these situations, cases of switching from one TNF-blocking agent to another are reported in rheumatoid arthritis, but there are few cases in JIA. This report documents the case of a patient with JIA who improved following a switch from etanercept to infliximab.

Publication types

Case Reports

MeSH terms

Adolescent
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Juvenile / drug therapy*
Arthritis, Juvenile / pathology
Arthritis, Juvenile / physiopathology
Drug Administration Schedule
Drug Resistance, Multiple
Drug Therapy, Combination
Etanercept
Female
Humans
Immunoglobulin G / therapeutic use*
Infliximab
Joints / drug effects
Joints / pathology
Magnetic Resonance Imaging
Methotrexate / therapeutic use
Prednisolone / therapeutic use
Receptors, Tumor Necrosis Factor / therapeutic use*

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Prednisolone
Infliximab
Etanercept
Methotrexate